Citations

Clear

24 citation(s) found for "Grossi, F".

Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD
Gu, Hyundam , Diaz, Luis Antonio, Baeza, Natalia, Idalsoaga, Francisco, Zheng, Ming‐Hua , Maiwall, Rakhi , Sarin, Shiv K., Kulkarni, Anand V., Ramyasri, Ramagundam, Tijera, Fátima Higuera de La, Pinto, Helena , Carvalhana, Sofia, Fernandes, Rita , Khan, Mohammad Qasim , Alazawi, William, Li, Wenhao, Temperley, Laura , Marti-Aguado, David, Gratacós-Ginès, Jordi, Montes, Pedro, Yip, Terry Cheuk‐Fung , Wong, Vincent Wai-Sun, Villela-Nogueira, Cristiane, Leite, Nathalie, Salles, Gil F. , Cardoso, Claudia Regina Lopes, Contreras, Daniza, Galimberti, Alceo, Bessone, Fernando, Valentin-Cortez, Francisco J , Mijangos-Trejo, Alejandra, Chavéz-Tapia, N, Simian, Daniela , Gil, Pamela, Mattos, Ângelo, Acuña, Johana , Araujo, Roberta Chaves, Ferraz, Igor Lima, Marrugo, Katherine, Torres, A , Torres, Juan Diego , Valdes, V., Córdova, Jacqueline, Mendizabal, Manual, Couto, Cláudia Alves , Cotter, Thomas G., Anouti, Ahmad , Rady, Elias D. , Patel, Sheel , Singal, Ashwani K., Parker, Richard, Ibrahim, Mohamad Ali , Jalal, Prasun K., Noureddin, Mazen, Alkhouri, Naim , Kamath, Patrick S. , Sanyal, Arun, Sterling, Richard K., Ajmera, Veeral, Loomba, Rohit, Arrese, Marco, Bataller, Ramón , Arab, Juan Pablo, Jalal, Prasun K , Cuyas, Berta , Cheuk-Fung Yip, Terry , Zheng, Ming-Hua , Díaz, Luis Antonio , Baeza, Natalia , Idalsoaga, Francisco , Zhou, Xiao-Dong , Sarin, Shiv Kumar , Kulkarni, Anand V., Ramyasri, Ramagundam, Carvalhana, Sofia , Alazawi, William , Li, Wenhao , Aguado, David Martí , Gratacós‐Ginès, Jordi , Pose, Elisa , Poca, María , Cuyàs, Berta , Barreyro, Fernando Javier , Ayares, Gustavo , Wong, Vincent Wai‐Sun , Wong, Grace Lai‐Hung , Lai, Jimmy Che‐To , Cardoso, Claudia R.L. , Velasco, J.A. Velarde-Ruiz , Galimberti, Alceo, Bessone, Fernando , Chávez-Tapia, Norberto Carlos , Ridruejo, Ezequiel , Peralta, Mirta , Roblero, Juan Pablo , El‐Kassas, Mohamed , Araújo, Roberta Chaves , Marrugo, Katherine , Mendizabal, Manuel , Cançado, Guilherme Grossi Lopes , Cotter, T G , Dahshi, Hamza , Singal, Ashwani K. , Pekarska, Katrīna , Jalal, Prasun K. , Castro-Narro, Graciela E , Noureddin, Mazen , Dunn, Winston , Sanyal, Arun J. , Sterling, Richard K. , Ajmera, Veeral , Loomba, Rohit , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology Communications | July 28, 2026 | Volume: 10 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000001020 | PMID 42520161 Get It

Background: Noninvasive tests are well validated in metabolic dysfunction–associated steatotic liver disease, but evidence in metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD) is limited. We evaluated noninvasive test–based clinical care pathways for fibrosis risk stratification in MetALD and ALD. Methods: This is a multinational, multicenter, cross-sectional study across 35 centers in 16 countries (2013–2025), including adults with MetALD or ALD. Fibrosis was assessed by liver biopsy and/or vibration-controlled transient elastography (VCTE). In biopsy-proven participants, we analyzed the sequential pathway (Fibrosis-4 [FIB-4] first, followed by VCTE for indeterminate FIB-4) to identify advanced fibrosis (≥F3). Diagnostic accuracy was assessed using the AUC. Results: Among 893 participants (41.3% MetALD and 58.7% ALD), the median age was 52 [43.0–61.0] years, and 79.4% were male. The estimated prevalence of advanced fibrosis was 45% (32.2% in MetALD and 54.0% in ALD). Participants with MetALD had a more dysmetabolic profile but lower fibrosis stages than ALD. Among biopsy-proven participants, FIB-4 AUC was 0.720, and VCTE AUC was 0.833. FIB-4 performed better in MetALD than ALD (AUC 0.773 vs. 0.540), while VCTE accuracy was similar across groups. In the sequential pathways, the false-negative rate for advanced fibrosis (misclassified as low risk) was 6.8% (4.9% MetALD and 11.3% ALD). Conclusions: In biopsy-proven patients, FIB-4 performance was acceptable in MetALD but substantially weaker in ALD. The standard 2-step pathway performed adequately in MetALD but missed a clinically meaningful proportion of advanced fibrosis in ALD.
Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”
Scherpereel, Arnaud , Mansfield, Aaron S. , Grossi, Francesco , Popat, Sanjay , Baas, Paul , Nowak, Anna K. , Tsao, Anne S. , Fujimoto, Nobukazu , Aragón, Yolanda Bautista, Talbot, Toby, Kaplan, Muhammet A., Soomro, Raheela, Hu, Nan , Ip, Virginia , Peters, Solange , Talbot, Toby , Kowalski, Dariusz , Cardona, Andrés F , Lee, Adam , Hung, Yu-Han , Zalcman, Gérard , Mansfield, Aaron S , Nowak, Anna K , Popat, Sanjay , Baas, Paul , Grossi, Francesco , Tsao, Anne S. , Peters, Solange , Bautista-Aragón, Yolanda, Kowalski, Dariusz M. , Cardona, Andrés F. , Zalcman, Gérard

Mayo Clinic

Journal of Clinical Oncology | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01153 | PMID 42430671 Get It

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Scherpereel, Arnaud , Baas, P., Nowak, Anna K. , Tsao, Anne S. , Fujimoto, Nobukazu, Peters, Solange , Mansfield, A., Popat, Sanjay , Aragón, Yolanda Bautista, Talbot, Toby , Kaplan, Muhammet A., Cardona, Andrés Felipe, Soomro, Raheela, Hu, Nan , Lee, Adam, Ip, Vladanov, Zalcman, G., Mansfield, Aaron S. , Baas, Paul , Baas, Paul , Mansfield, Aaron S , Grossi, Francesco , Kowalski, Dariusz , Cardona, Andrés F , Lee, Adam , Hung, Yu-Han , Zalcman, Gérard , Nowak, Anna K , Popat, Sanjay , Tsao, Anne S. , Scherpereel, Arnaud , Fujimoto, Nobukazu , Peters, Solange , Bautista-Aragón, Yolanda, Grossi, Francesco , Kowalski, Dariusz M. , Ip, Virginia , Zalcman, Gérard

Mayo Clinic

Journal of Clinical Oncology | February 24, 2026 | Volume: 44 | Issue: 9 | Pages: 742-749

10.1200/jco-25-01328 | PMID 41734361 Get It

In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-switching analyses with first-line nivolumab plus ipilimumab versus chemotherapy. With a median follow-up of 66.8 months, nivolumab plus ipilimumab demonstrated continued overall survival (OS) benefit versus chemotherapy in all randomly assigned patients (5-year OS rates, 14% v 6%; hazard ratio [HR], 0.74 [95% CI, 0.62 to 0.88]); similar benefit was observed regardless of tumor histology. Of biomarker-evaluable patients treated with nivolumab plus ipilimumab (n = 242), high baseline monocytic myeloid-derived suppressor cell (M-MDSC) levels correlated with worse OS versus low M-MDSC levels (HR, 1.25 [95% CI, 1.09 to 1.43]). After adjusting for 24% of patients in the chemotherapy arm who received subsequent immunotherapy, nivolumab plus ipilimumab demonstrated continued OS benefit versus chemotherapy (HR, 0.64 [95% CI, 0.53 to 0.78]). No new safety signals were observed. These results demonstrate long-term, durable clinical benefit with nivolumab plus ipilimumab versus chemotherapy, which continued to be preserved even after treatment-switching adjustment in the chemotherapy arm. Exploratory analyses suggested greater benefit with nivolumab plus ipilimumab in the low M-MDSC subgroup. These results further support first-line nivolumab plus ipilimumab as standard of care for unresectable PM.
Efficacy and Safety of Obeticholic Acid as Second‐Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta‐Analysis
Abreu, Eliabe Silva de , Fernandes, Gabriel Prusch, Lacerda, Henrique , Reginato, Pedro Henrique , Gonzalez, Carlos, Eaton, John E. , Cançado, Guilherme Grossi Lopes , Abreu, Eliabe S , Sanchez Gonzalez, Carlos Danilo, Cançado, Guilherme Grossi Lopes , Fernandes, Gabriel Prusch, Neves, Henrique Alexsander Ferreira , Gonzalez, Carlos Danilo Sanchez

Mayo Clinic

Journal of Gastroenterology and Hepatology | September 30, 2025 | Volume: 40 | Issue: 12 | Pages: 2820-2829

10.1111/jgh.70094 | PMID 41025397 Get It

ABSTRACT Background Obeticholic acid (OCA) was conditionally approved in 2016 as a second‐line therapy for patients with primary biliary cholangitis (PBC) and incomplete response to ursodeoxycholic acid (UDCA) monotherapy. We aimed to evaluate the impact of OCA add‐on therapy on biochemical outcomes and safety in those patients. Methods We systematically searched MEDLINE, Embase, and Cochrane CENTRAL for papers published up to October 29, 2024, evaluating OCA in patients with PBC at the 12‐month timepoint. Pooled analyses of liver enzymes were performed using the standard mean difference (SMD) and 95% confidence interval (CI) from the OCA baseline. Side effects and the achievement of criteria for adequate response are presented in percentages (95% CI). Results We included 1285 patients from 10 studies, two of which were RCTs. The addition of OCA significantly reduced alkaline phosphatase (ALP) (SMD −0.86; −1.15 to −0.56; p < 0.001) and total bilirubin (SMD −0.29; −0.43 to −0.15; p < 0.001). Overall, 37.23% of the patients (95% CI 31.47–43.39) responded to OCA (POISE criteria). The response rate was greater in the POISE trial results compared with real‐world data (46.15% vs. 30.54%, respectively; p = 0.0089). Pruritus was the most common adverse event (40.23%; 24.65–58.07). Approximately one‐fifth of the patients stopped OCA (18.05%; 12.72–24.99), with pruritus being the main reason for discontinuation (47.70%; 34.15–61.60). Conclusion Adding OCA improves ALP, bilirubin, and biochemical remission rates in patients with PBC who did not respond well to UDCA monotherapy. Real‐world data show an attenuated response. Pruritus is the most common side effect and the leading cause of drug discontinuation.
DISCO App: A patient intervention to reduce the financial burden of cancer in a diverse patient population.
Hamel, Lauren M. , Dougherty, David W. , Heath, Elisabeth I. , Mabunda, Lorna, Austin, Teneisha , Assad, Hadeel , Tadesse, Eyouab, Grossi, Roman , Jarbo, Nouran, Eggly, Susan , Kim, Seongho , Mamdani, Hirva Mansurali

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps1659 Get It

TPS1659 Background: Financial toxicity, the material and psychological burden of treatment cost, affects up to half of people with cancer and can affect adherence and survival. Financial toxicity is a health equity issue, disproportionately affecting Black patients. Patient education about cost and patient-provider cost discussions are recommended to mitigate financial toxicity but occur infrequently. Our goal is to mitigate financial toxicity through a tailorable education and communication intervention, the DISCO App. The DISCO App was shown to be feasible, acceptable, and preliminarily effective at prompting cost discussions and improving related outcomes in a pilot trial. The aim of the ongoing trial is to test the effectiveness of the DISCO App on short- and longer-term outcomes for Black and White patients with cancer. Methods: This study is a longitudinal RCT. Oncologists are eligible if they treat patients with solid tumors at the trial site. Patients of participating oncologists are eligible if they are ≥ 18 years of age; identify as Black or White; can read and write in English; have an email address; and were diagnosed with a solid tumor for which systemic therapy is a likely recommended treatment. Strata were created to balance arms by patient race, income, age, and sex. Upon consent, patients are randomized to one usual care arm (1) or one of two intervention arms (2 and 3). All patients are asked to allow one treatment discussion with their oncologist to be video recorded for analysis. Prior to the recording, intervention patients utilize the DISCO App on an iPad. The DISCO App includes a video about treatment costs, ways to manage costs, and the importance of discussing costs with oncologists. Once patients enter their socio-demographic information (e.g., employment, insurance) and any financial concerns, they receive a tailored list of questions to ask their oncologist. Arm 3 patients receive an intervention booster via email two months after the recording. Patients complete measures at baseline, right after the recording, and at 1, 3, 6 and 12 months after the recording. Measures assess outcomes including cost discussions, communication quality, cost knowledge, self-efficacy for cost management, referrals for support, short- and longer-term financial toxicity, and treatment adherence. The patient-oncologist interaction is the unit of analysis and we will use multi-linear models to compare outcomes by arm. We anticipate recruiting up to 15 oncologists and 240 patients. Data collection began in March 2021 and will continue until July 2025. Participants to date include 13 oncologists and 192 patients (116 Black, 76 White). Most patients completed the baseline assessment (n=164), the post-interaction assessment (n=137), and at least 1 follow-up assessment (n=132); 125 treatment discussions have been recorded. The IRB reviewed the trial in December 2024 and approved continuation. Clinical trial information: NCT04766190 .
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia
Roman, Eloy, Shum, M., Hanna, Wahid T., Araujo, Sérgio , Al-Adhami, Mohammed , Grossi, F , Gertz, Morie A. , Fattizzo, Bruno , Lentz, Steven R , Gertz, Morie A

Mayo Clinic

Blood | November 1, 2024 | Volume: 145 | Issue: 4 | Pages: 397-408

10.1182/blood.2023022549 | PMID 39486046 Get It

Abstract Cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) are rare autoimmune hemolytic anemias characterized by red blood cell destruction, largely attributable to complement activation resulting in intravascular and extravascular hemolysis. Pegcetacoplan is a subcutaneously administered C3-targeted therapy, which may be suitable for treating CAD and wAIHA. In this open-label phase 2 study, analyses were conducted in 2 cohorts, 1 for patients with CAD and the other for those with wAIHA. In each cohort, patients were randomly assigned to receive pegcetacoplan 270 mg/d or 360 mg/d for up to 48 weeks. Safety end points included the incidence and severity of treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI). Efficacy end points included change from baseline in hemoglobin (Hb), lactate dehydrogenase, absolute reticulocyte count, haptoglobin, indirect bilirubin, and functional assessment of chronic illness therapy (FACIT)-fatigue scale. Thirteen of 13 (100%) and 10 of 11 (91%) patients with CAD and wAIHA, respectively, experienced at least 1 TEAE. Ten patients had at least 1 serious AE; none were considered related to pegcetacoplan. The only treatment-related AESIs were injection site reactions. Pegcetacoplan increased Hb levels, reduced hemolysis, and increased FACIT-fatigue scale scores in the first weeks; at week 48 the median (interquartile range) change from baseline Hb for the CAD and wAIHA total groups was 2.4 (0.90-3.00) and 1.7 g/dL (−1.40 to 2.90), respectively, and improvements in hemolysis and FACIT-fatigue scale scores were maintained. This study demonstrated that pegcetacoplan is generally well tolerated and suggests it can be effective for patients with CAD and wAIHA. This trial was registered at www.ClinicalTrials.gov as #NCT03226678.
Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors
Sotelo, Carolina , Vallejo-Ardila, Dora L. , Ruíz-Patiño, Alejandro , Rodríguez, July, Isaza, Hernán Carranza , Otero, Jorge, Archila, Pilar , Rojas, Leonardo , Zuluaga, Jairo , Gómez, Cladelis Rubio , García-Robledo, Juan Esteban , Espinosa, Sergio Andrés Mejía , Jaller, Elvira , Cardona, Andrés F. , Sotelo-Rodríguez, Carolina , Vallejo-Ardila, Dora , Carranza, Hernán , Rojas, Leonardo , Rubio, Cladelis , Ordóñez-Reyes, Camila , Garcia-Robledo, Juan Esteban , Mejía, Sergio , Jaller, Elvira , Arrieta, Oscar , Cardona, Andrés F , Pérez, Darwin Andrés Moreno , Carranza, Hernán, Vargas, Carlos, Ordóñez‐Reyes, Camila , Arrieta, Óscar

Mayo Clinic

JCO Global Oncology | January 18, 2024 | Volume: No volume available | Issue: 10 | Pages: No page available

10.1200/go.23.00011 | PMID 38237094 Get It

PURPOSE Multidisciplinary molecular tumor boards (MTBs) decode complex genomic data into clinical recommendations. Although MTBs are well-established in the oncology practice in developed countries, this strategy needs to be better explored in developing countries. Herein, we describe the possible benefits and limitations of the first MTB established in Colombia. METHODS Demographic, clinical, and genomic information was collected between August 2020 and November 2021. By mid-2020, an MTB strategy was created to discuss clinical cases with one or more genomic alterations identified by next-generation sequencing using an open-access virtual platform. We characterized the patient population as benefiting from the recommended treatment option. We assessed the benefits and access to available targeted therapies that have the potential to change clinical management by making recommendations to treating oncologists on the basis of genomic profiling. However, we did not assess the treatment oncologists' compliance with MTB recommendations because they were not intended to replace clinical judgment/standard of care. RESULTS A total of 146 patients were included in the discussions of the MTB. The median age was 59 years, and 59.6% were women. Genomic results prompting a change in therapeutic decisions were obtained in 53.1% of patients (95% CI, 44.9 to 61.3). The most prevalent malignancy was non–small-cell lung cancer (51%). Other malignancies represented 60%, 50%, and 30% of patients with soft-tissue sarcomas, brain tumors, and breast cancer, respectively. CONCLUSION Using an open-access virtual platform, MTBs were feasible in low- and middle-income countries on the basis of the capability to provide the benefits and access to available targeted therapies that are not standard of care. Furthermore, MTB recommendations were made available to the treating oncologist in different locations across Colombia, providing the option to modify clinical management in most of these patients.
First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Scherpereel, Arnaud , Antonia, Scott , Bautista, Y., Zalcman, Gérard , Sun, Xuezheng , Padilla, Brad , Aanur, Praveen , Daumont, M. , Bennett, Bryan , McKenna, M., Baas, P, Zalcman, Gérard , Bischoff, Hervé , Grossi, Francesco , Kowalski, Dariusz M. , Nowak, Anna K. , Fujimoto, Nobukazu , Peters, Solange , Tsao, Anne S. , Mansfield, Aaron S. , Popat, Sanjay , Bennett, B, Baas, P

Mayo Clinic

Pneumologie | October 26, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1723293 Get It

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country
Cifuentes, Claudia , Lombana, Milton , Vargas, Henry , Laguado, Paola, Ruíz-Patiño, Alejandro , Rojas, Leonardo , Navarro, Uriel, Ricaurte, Luisa , Zatarain-Barrón, Lucía, Zapata, Leandro, González, Guido, Bernal, Laura , Restrepo, Juan G., Viola, Lucía , Grosso, Fabio, Zapata, Ricardo , Mantilla, William, Carranza, Hernán, Bustillo, Iván, Quintero, Néstor Llinás , Duarte, Ricardo , Rodríguez, July, Archila, Pilar , Ávila, Jenny , Gámez, Tatiana , Sotelo, Carolina , Otero, Jorge, Forero, Elkin, Limpias, Catalina, Cardona, Andrés F. , Group, ONCOL, CLICaP, Ordóñez-Reyes, Camila , Cardona, Andrés F , Sotelo-Rodríguez, Carolina , Rojas, Leonardo , Vargas, Carlos, Arrieta, Óscar , Zapata, Leandro, Ortiz, Carlos, Duarte, Ricardo, Bermúdez, Maritza , Lema, Mauricio , Ordóñez‐Reyes, Camila , Mejía, Sergio, Rolfo, Christian , Rosell, Rafael , Group, ONCOL, CLICaP

Mayo Clinic

Cancer Control | May 6, 2023 | Volume: 30 | Issue: No issue available | Pages: No page available

10.1177/10732748231175256 | PMID 37148308 Get It

Purpose Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country. Methods In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians’ request in the clinical care for therapy decisions. Kaplan–Meier survival curves were estimated to characterize the time-to-event variables. Results Patients median age was 61 years (range: 14–87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment ( P = .7). Conclusion CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients.